Diplomat Pharmacy, Inc. revised earnings guidance for the full-year 2019. The company now expects revenue between $4.9 and $5.1 billion, versus the previous range of $4.7 and $5.0 billion. Net loss between $368 million and $361 million, versus the previous range of $201 million and $191 million. Diluted loss per share between $4.91 and $4.81, versus the previous range of $2.69 and $2.55.

For the quarter, the company reported goodwill impairments of $122,076,000 and impairments of definite-lived intangible assets of $34,173,000 .